Published on 06/12/2025

Use of Modeling in Filings: What’s Acceptable Today

The pharmaceutical industry continually strives for improved methodologies in process and product validation, particularly in the context of extractables and leachables (E&L). Understanding what is acceptable in regulatory submissions is essential for ensuring compliance with the stringent expectations from regulatory agencies such as the FDA, EMA, and MHRA. This article aims to provide a thorough, step-by-step guide on utilizing modeling in E&L filings, focusing on key components like analytical evaluation thresholds (AET) and dose-based thresholds (DBT) while also addressing container closure integrity (CCI) and single-use systems validation.

Step 1: Understanding Extractables and Leachables

Extractables and leachables are critical factors in pharmaceutical packaging. Extractables are the compounds that can be extracted from packaging materials under specific conditions. In contrast, leachables are the compounds that migrate into the drug product over time. Regulatory expectations necessitate a fundamental understanding of these concepts, as they can impact patient safety and product efficacy.

To comply with regulations such as the FDA’s guidance on E&L, companies must undertake comprehensive risk assessments. A well-structured assessment will take into account the nature of the drug product being packaged, the materials of the container closure system, and the manufacturing process involved.

Step 2: Risk Assessment Methodologies

Conducting an E&L risk assessment is the corner stone of a comprehensive evaluation strategy. This involves determining the potential for extractables and leachables to impact the drug product. Risk assessments should consider the following:

• The specific materials used in packaging
• Storage and transport conditions
• Intended use and exposure scenario

Implementing a systematic approach allows for the identification of high-risk components that need thorough testing. Additionally, utilizing models can help predict E&L profiles based on known data, thus optimizing testing requirements and timelines.

Step 3: Establishing Analytical Evaluation Thresholds (AET)

The establishment of an Analytical Evaluation Threshold (AET) is essential when evaluating the safety of leachables detected in drug products. The AET is a predetermined threshold value that helps in defining whether identified leachables can be quantitatively assessed or neglected as non-relevant.

To calculate the AET, companies often refer to existing guidelines including those detailed by USP and the PQRI (Product Quality Research Institute) guidance. The determination of AET involves:

1. Identifying the therapeutic context of the drug product.
2. Determining the maximum daily dose.
3. Calculating acceptable daily intake (ADI) based on toxicological data.

The model generally tends to align with the expected therapeutic dose and safety margins. As a benchmark, the AET should not exceed 1.5 µg per day for most pharmaceutical products, but this may vary based on specific regulatory expectations across regions, such as in the context of EU GMP Annex 1.

Step 4: Dose-Based Threshold (DBT) Development

In addition to the AET, the Dose-Based Threshold (DBT) is an important aspect of E&L evaluation, particularly for products administered via parenteral routes. While designing experiments for DBT, focus should be given to:

• Establishing the relationship between daily dose and acceptable levels of leachables.
• Conducting quantitative leachables testing relevant to the predicted concentrations in the drug product.
• Reference established toxicological limits to justify safe thresholds.

Developing a defensible DBT subserves the dual purpose of assisting in regulatory compliance while ensuring patient safety. As such, the DBT must align with AET, ensuring harmonization in assessments.

Step 5: Container Closure Integrity (CCI) Testing

Container Closure Integrity (CCI) is integral to maintaining the quality and safety of drug products. CCI testing assesses whether the packaging can protect the product from external contaminants, including E&L, throughout its shelf life. Effective CCI testing strategies should encompass:

• Validation of sealing methods used in production
• Environmental stresses influenced by storage conditions
• Testing methodologies that may include dye ingress tests, vacuum decays, and helium leak tests

Regulatory bodies expect CCI testing to confirm that the package maintains its integrity. The USP guidelines provide several methods for CCI evaluation, ensuring compliance with both US and EU standards.

Step 6: Validation of Single-Use Systems

The use of single-use systems in pharmaceutical manufacturing has seen an upward trend. Their validation, particularly for E&L, poses unique challenges. Key aspects of single-use systems validation include:

• Performing E&L studies to assess the risk posed by single-use components.
• Utilizing modeling approaches to predict the impact of various drug products on single-use systems.
• Documenting compliance with guidelines such as the FDA process validation requirements and specific analytical protocols.

Compliance with these protocols ensures that potential leachables do not interfere with drug efficacy. The integrated approach involving thorough validation and appropriate risk assessment mitigates risks associated with single-use technologies.

Step 7: Submitting Data to Regulatory Authorities

Once data is compiled from the previous stages, companies must prepare submissions for regulatory reviews. The process of documenting and presenting your findings should follow a structured format:

• Summary of risk assessments and methodologies used
• Detailed results of leachables testing, including AET and DBT evaluations
• CCI testing outcomes with complete procedural descriptions

Clear presentation is vital for gaining approval from regulatory authorities. Given the global regulatory landscape, ensuring harmonized data presentation can enhance compliance with varying expectations of the FDA, EMA, and MHRA.

Conclusion: Best Practices and Future Considerations

The use of modeling in filings is a powerful approach that can simplify complex E&L challenges. By consulting recent guidelines and conducting robust risk assessments, pharmaceutical professionals can ensure a regulatory-compliant framework that facilitates thorough and defensible submissions.

Continued advancements in analytical techniques and modeling approaches will contribute dramatically to the field of pharmaceutical validation. Adhering to best practices not only secures compliance but ultimately advances the industry towards safer pharmaceutical products.